Combination of EP4 antagonist MF-766 and anti-PD-1 promotes anti-tumor efficacy by modulating both lymphocytes and myeloid cells

Combination of EP4 antagonist MF-766 and anti-PD-1 promotes anti-tumor efficacy by modulating both lymphocytes and myeloid cells

Prostaglandin E2 (PGE2), an arachidonic acid pathway metabolite produced by cyclooxygenase (COX)-1/2, has been shown to impair anti-tumor immunity through engagement with one or more E-type prostanoid receptors (EP1-4). Specific targeting of EP receptors, as opposed to COX-1/2 inhibition, has been p...

Full description

Bibliographic Details
Main Authors: Yun Wang, Long Cui, Peter Georgiev, Latika Singh, Yanyan Zheng, Ying Yu, Jeff Grein, Chunsheng Zhang, Eric S. Muise, David L. Sloman, Heidi Ferguson, Hongshi Yu, Cristina St. Pierre, Pranal J Dakle, Vincenzo Pucci, James Baker, Andrey Loboda, Doug Linn, Christopher Brynczka, Doug Wilson, Brian B Haines, Brian Long, Richard Wnek, Svetlana Sadekova, Michael Rosenzweig, Andrew Haidle, Yongxin Han, Sheila H. Ranganath
Format: Article
Language:English
Published: Taylor & Francis Group 2021-01-01
Series:OncoImmunology
Subjects:
immunotherapy
ep4 antagonism
pge2
myeloid cells
lymphocytes
Online Access:http://dx.doi.org/10.1080/2162402X.2021.1896643

Internet

http://dx.doi.org/10.1080/2162402X.2021.1896643

Similar Items